{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T05:22:33Z","timestamp":1784524953800,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,2,20]],"date-time":"2014-02-20T00:00:00Z","timestamp":1392854400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-244x-14-50","type":"journal-article","created":{"date-parts":[[2014,2,20]],"date-time":"2014-02-20T07:03:44Z","timestamp":1392879824000},"source":"Crossref","is-referenced-by-count":15,"title":["CYP1A2polymorphism \u22121545C\u2009>\u2009T (rs2470890) is associated with increased side effects to clozapine"],"prefix":"10.1186","volume":"14","author":[{"given":"Merja","family":"Viikki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli","family":"Kampman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niko","family":"Sepp\u00e4l\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Mononen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terho","family":"Lehtim\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esa","family":"Leinonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,2,20]]},"reference":[{"issue":"11","key":"1561_CR1","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1517\/14656566.2011.626769","volume":"13","author":"L Citrome","year":"2012","unstructured":"Citrome L: A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. Expert Opin Pharmacother. 2012, 13 (11): 1545-1573. 10.1517\/14656566.2011.626769.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"1561_CR2","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1208\/s12248-009-9127-y","volume":"11","author":"SF Zhou","year":"2009","unstructured":"Zhou SF, Yang LP, Zhou ZW, Liu YH, Chan E: Insights into the Substrate Specificity, Inhibitors, Regulation, and Polymorphisms and the Clinical Impact of Human Cytochrome P450 1A2. AAPS J. 2009, 11 (3): 481-494. 10.1208\/s12248-009-9127-y.","journal-title":"AAPS J"},{"key":"1561_CR3","doi-asserted-by":"publisher","first-page":"625","DOI":"10.2217\/14622416.9.5.625","volume":"9","author":"A Gunes","year":"2008","unstructured":"Gunes A, Dahl ML: Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics. 2008, 9: 625-637. 10.2217\/14622416.9.5.625.","journal-title":"Pharmacogenomics"},{"key":"1561_CR4","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.pharmthera.2007.09.004","volume":"116","author":"M Ingelman-Sundberg","year":"2007","unstructured":"Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C: Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007, 116: 496-526. 10.1016\/j.pharmthera.2007.09.004.","journal-title":"Pharmacol Ther"},{"key":"1561_CR5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1093\/oxfordjournals.jbchem.a022352","volume":"125","author":"M Nakajima","year":"1999","unstructured":"Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T: Genetic polymorphism in the 5\u2032-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem. 1999, 125: 803-808. 10.1093\/oxfordjournals.jbchem.a022352.","journal-title":"J Biochem"},{"issue":"4","key":"1561_CR6","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1046\/j.1365-2125.1999.00898.x","volume":"47","author":"C Sachse","year":"1999","unstructured":"Sachse C, Brockm\u00f6ller J, Bauer S, Roots I: Functional significance of a C\u2013-\u2009>\u2009A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol. 1999, 47 (4): 445-449.","journal-title":"Br J Clin Pharmacol"},{"key":"1561_CR7","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1097\/01.jcp.0000116646.91923.2f","volume":"24","author":"CB Eap","year":"2004","unstructured":"Eap CB, Bender S, Jaquenoud Sirot E, Cucchia G, Jonzier-Perey M, Baumann P, Allorge D, Broly F: Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol. 2004, 24: 214-219. 10.1097\/01.jcp.0000116646.91923.2f.","journal-title":"J Clin Psychopharmacol"},{"key":"1561_CR8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/00004714-200112000-00011","volume":"21","author":"V Ozdemir","year":"2001","unstructured":"Ozdemir V, Kalow W, Okey AB, Lam MS, Albers LJ, Reist C, Fourie J, Posner P, Collins EJ, Roy R: Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C\u2009>\u2009A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. J Clin Psychopharmacol. 2001, 21: 603-607. 10.1097\/00004714-200112000-00011.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"1561_CR9","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/sj.mp.4000736","volume":"5","author":"VS Basile","year":"2000","unstructured":"Basile VS, Ozdemir V, Masellis M, Walker ML, Meltzer HY, Lieberman JA, Potkin SG, Alva G, Kalow W, Macciardi FM, Kennedy JL: A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry. 2000, 5 (4): 410-417. 10.1038\/sj.mp.4000736.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"1561_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/sj.tpj.6500282","volume":"5","author":"AK Tiwari","year":"2005","unstructured":"Tiwari AK, Deshpande SN, Rao AR, Bhatia T, Mukit SR, Shriharsh V, Lerer B, Nimagaonkar VL, Thelma BK: Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism. Pharmacogenomics J. 2005, 5 (1): 60-69. 10.1038\/sj.tpj.6500282.","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"1561_CR11","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.psychres.2013.02.030","volume":"209","author":"FB Kohlrausch","year":"2013","unstructured":"Kohlrausch FB, Severino-Gama C, Lobato MI, Belmonte-de-Abreu P, Carracedo A, Hutz MH: The CYP1A2\u2013163C\u2009>\u2009A polymorphism is associated with clozapine-induced generalized tonic-clonic seizures in Brazilian schizophrenia patients. Psychiatry Res. 2013, 209 (2): 242-245. 10.1016\/j.psychres.2013.02.030.","journal-title":"Psychiatry Res"},{"issue":"3","key":"1561_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.psychres.2011.03.011","volume":"189","author":"E Bolla","year":"2011","unstructured":"Bolla E, Bortolaso P, Ferrari M, Poloni N, Callegari C, Marino F, Lecchini S, Vender S, Cosentino M: Are CYP1A2*1\u00a0F and *1C associated with clozapine tolerability?: a preliminary investigation. Psychiatry Res. 2011, 189 (3): 483-10.1016\/j.psychres.2011.03.011.","journal-title":"Psychiatry Res"},{"issue":"2\u20133","key":"1561_CR13","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.psychres.2012.07.002","volume":"200","author":"M Ferrari","year":"2012","unstructured":"Ferrari M, Bolla E, Bortolaso P, Callegari C, Poloni N, Lecchini S, Vender S, Marino F, Cosentino M: Association between CYP1A2 polymorphisms and clozapine-induced adverse reactions in patients with schizophrenia. Psychiatry Res. 2012, 200 (2\u20133): 1014-1017.","journal-title":"Psychiatry Res"},{"issue":"5","key":"1561_CR14","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/sj.tpj.6500415","volume":"7","author":"AK Tiwari","year":"2007","unstructured":"Tiwari AK, Deshpande SN, Lerer B, Nimgaonkar VL, Thelma BK: Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545C\u2009>\u2009T polymorphism. Pharmacogenomics J. 2007, 7 (5): 305-311. 10.1038\/sj.tpj.6500415.","journal-title":"Pharmacogenomics J"},{"issue":"5","key":"1561_CR15","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1192\/bjp.166.5.650","volume":"166","author":"JC Day","year":"1995","unstructured":"Day JC, Wood G, Dewey M, Bentall RP: A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry. 1995, 166 (5): 650-653. 10.1192\/bjp.166.5.650.","journal-title":"Br J Psychiatry"},{"key":"1561_CR16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/hup.495","volume":"5","author":"TJ Lambert","year":"2003","unstructured":"Lambert TJ, Cock N, Alcock SJ, Kelly DL, Conley RR: Measurement of antipsychotic-induced side effects: support for the validity of a self-report (LUNSERS) versus structured interview (UKU) approach to measurement. Hum Psychopharmacol. 2003, 5: 405-411.","journal-title":"Hum Psychopharmacol"},{"key":"1561_CR17","first-page":"262","volume-title":"Forensic Toxicology: Proceedings of the 29th TIAFT International Meeting, June 24th-27th 1991","author":"U-M Laakkonen","year":"1991","unstructured":"Laakkonen U-M, Heiskanen A: Screening and quantitation of benzodiazepines in serum samples. Forensic Toxicology: Proceedings of the 29th TIAFT International Meeting, June 24th-27th 1991. Edited by: Kaempe B. 1991, Copenhagen, Denmark: Mackeenzie, 262-266."},{"key":"1561_CR18","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/0197-2456(90)90005-M","volume":"11","author":"WD Dupont","year":"1990","unstructured":"Dupont WD, Plummer WD: Power and sample size calculations, A Review and Computer Program. Contr Clin Trials. 1990, 11: 116-128. 10.1016\/0197-2456(90)90005-M.","journal-title":"Contr Clin Trials"},{"key":"1561_CR19","doi-asserted-by":"publisher","first-page":"697","DOI":"10.4088\/JCP.v68n0506","volume":"68","author":"KI Melkersson","year":"2007","unstructured":"Melkersson KI, Scordo MG, Gunes A, Dahl ML: Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients. J Clin Psychiatry. 2007, 68: 697-704. 10.4088\/JCP.v68n0506.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"1561_CR20","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1600-0773.1999.tb02016.x","volume":"85","author":"NH Sepp\u00e4l\u00e4","year":"1999","unstructured":"Sepp\u00e4l\u00e4 NH, Leinonen EV, Lehtonen ML, Kivist\u00f6 KT: Clozapine serum concentrations are lower in smoking than in non-smoking schizophrenic patients. Pharmacol Toxicol. 1999, 85 (5): 244-246.","journal-title":"Pharmacol Toxicol"},{"issue":"2","key":"1561_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2165\/00003088-200039020-00004","volume":"39","author":"JA Carrillo","year":"2000","unstructured":"Carrillo JA, Benitez J: Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet. 2000, 39 (2): 127-153. 10.2165\/00003088-200039020-00004.","journal-title":"Clin Pharmacokinet"},{"key":"1561_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1742-7843.2004.pto940104.x","volume":"1","author":"K Raaska","year":"2004","unstructured":"Raaska K, Raitasuo V, Laitila J, Neuvonen PJ: Effect of caffeine-containing versus decaffeinated coffee on serum clozapine concentrations in hospitalised patients. Basic Clin Pharmacol Toxicol. 2004, 1: 13-18.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1561_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1081\/DMR-120001392","volume":"34","author":"S Rendic","year":"2002","unstructured":"Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002, 34: 83-448. 10.1081\/DMR-120001392.","journal-title":"Drug Metab Rev"},{"issue":"1","key":"1561_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/jat\/21.1.73","volume":"21","author":"KS Patrick","year":"1997","unstructured":"Patrick KS, Markowitz JS: Potential for overestimation of clozapine concentration. J Analytical Toxicol. 1997, 21 (1): 73-75.","journal-title":"J Analytical Toxicol"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-14-50.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-244X-14-50\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-14-50","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,7,10]],"date-time":"2016-07-10T08:31:57Z","timestamp":1468139517000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/1471-244X-14-50"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,20]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1561"],"URL":"https:\/\/doi.org\/10.1186\/1471-244x-14-50","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,20]]},"article-number":"50"}}